Clinical Trials Logo

Filter by:
NCT ID: NCT03649438 No longer available - Clinical trials for Relapsed Neuroblastoma

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

NCT ID: NCT03672968 No longer available - Clinical trials for Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)

EAP_GS010_single Patient

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access Use for a single patient of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected with G11778A ND4 Leber Hereditary Optic Neuropathy

NCT ID: NCT03702036 No longer available - Solid Tumours Clinical Trials

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.

NCT ID: NCT03706573 No longer available - Clinical trials for HR+ Advanced or Metastatic Breast Cancer

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this Cohort Treatment Plan is to allow access to alpelisib for eligible patients diagnosed with hormone receptor positive, advanced or metastatic breast cancer harboring a phosphatidylinositol 3-kinase (PI3K)CA mutation. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

NCT ID: NCT03717181 No longer available - Polycystic Kidney Clinical Trials

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Start date: n/a
Phase:
Study type: Expanded Access

Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.

NCT ID: NCT03723057 No longer available - Clinical trials for Acute Myeloid Leukemia

Expanded Access for AG-221

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

NCT ID: NCT03723083 No longer available - Other Clinical Trials

Expanded Access for CC-2001

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-2001.

NCT ID: NCT03723096 No longer available - Multiple Myeloma Clinical Trials

Expanded Access for CC-4047

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.

NCT ID: NCT03724227 No longer available - Clinical trials for Myelodysplastic Syndrome

Expanded Access for ACE-011

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

NCT ID: NCT03740516 No longer available - Bechet's Disease Clinical Trials

Expanded Access for CC-10004

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.